Low-density lipoprotein (LDL) cholesterol (LDL-C) is a risk factor for cardiovascular disease (CVD). Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) lower LDL-C concentrations by about 30-50% and have been shown to reduce mortality in patients with prevalent CVD. However, it is not clear whether statin treatment is benefi cial in a primary prevention setting, that is in people without prevalent CVD who are at relatively lower risk. The recent results of the JUPITER trial 1 have fuelled an intense debate whether statins should be given for primary prevention of CVD.
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Context
Low-density lipoprotein (LDL) cholesterol (LDL-C) is a risk factor for cardiovascular disease (CVD). Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) lower LDL-C concentrations by about 30-50% and have been shown to reduce mortality in patients with prevalent CVD. However, it is not clear whether statin treatment is benefi cial in a primary prevention setting, that is in people without prevalent CVD who are at relatively lower risk. The recent results of the JUPITER trial 1 have fuelled an intense debate whether statins should be given for primary prevention of CVD.
Methods
The authors performed a literature search in MEDLINE and Cochrane Collaboration databases to identify randomised controlled trials of statin use comprising patients without prevalent CVD at baseline. For trials partly containing CVD patients, the authors obtained tabular data for the individuals without a history of CVD. A meta-analysis was performed using both random effects and fi xed effects models. The primary outcome of interest was allcause mortality. Potential publication bias was assessed by the funnel plot and Egger's test.
Findings
The authors indentifi ed 11 studies that met their inclusion criteria and that provided the required data, two of them containing only patients with diabetes. In total, 65 229 patients with an average follow-up of 3.7 years were analysed, resulting in approximately 244 000 person-years of observation. Mean age at recruitment varied from 51 to 75 years. The age at time of recruitment was the only baseline correlate of mortality, while LDL-C concentration was not predictive of mortality. Statin therapy was not associated with a signifi cant survival benefi t (RR for statin users compared to non-users of: 0.91, 95% CI 0.83 to 1.01; and 0.93, 95% CI 0.86 to 1.00, in random effects and fi xed effects models, respectively). The exclusion of the two trials comprising only patients with diabetes did not substantively change these results. Furthermore, the authors did not fi nd a correlation between mortality reduction and baseline LDL-C concentration or with relative LDL-C reduction in the treatment arm. A relevant publication bias could not be detected.
Commentary
The authors present a meta-analysis of the effects of statin treatment on all-cause mortality in intermediate to highrisk patients without prevalent CVD. This investigation is by far the largest analysis of statin therapy in a purely primary prevention setting. Although the cohorts varied considerably with respect to the recruitment strategy, mean age and cardiovascular risk profi le, the authors observed a consistent null result (for statin benefi t) independent of mean baseline LDL concentration and mean LDL-C reduction in the treatment arm and without evidence of relevant heterogeneity across cohorts. A non-signifi cant ~8% risk reduction in a study of this size excludes a clinically relevant survival benefi t for statin therapy in the assessed population over the limited observation time.
This study therefore questions the widespread practice of prescribing statins to middle-aged patients with an average cardiovascular risk profi le who do not have overt CVD. The cohorts included in the meta-analysis had a mean mortality of 11.4/1000 person-years (in the placebo-arms), and therefore represent an intermediate to high-risk population. The inference can be made that individuals with lower cardiovascular risk are likely to benefi t even less from statin therapy.
Nevertheless, there are some questions that this study cannot answer. First, the mean follow-up is only 3.7 years, hence conclusions on potential long-term benefi ts of statin intake cannot be drawn. Some investigators argue that long-term exposure to higher LDL cholesterol is likely to Taken together, the study is the fi rst to meta-analyse statin therapy in a purely primary prevention setting. Its conclusive null result (for statin benefi t on all-cause mortality) raises important questions about the current practice of widespread use of statins for primary prevention of CVD in individuals with average cardiovascular risk.
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drug toxicity that may be accumulating over years of statin intake, including risk of developing diabetes. 2 Longterm studies are warranted to address this issue. Second, allcause mortality is an end point that has a low frequency in a primary prevention setting. Major cardiovascular events and cardiovascular morbidity (and associated impairment in quality of life) may be important outcomes that more closely refl ect treatment benefi ts in a primary prevention population seen in general practice. Third, since the meta-analysis did not have access to individual-level data, subgroup analyses (such as stratifi ed by gender, age, risk profi le) could not be performed. This study cannot answer the crucial question if there are select subgroups that may actually benefi t from statin therapy in a primary prevention setting. 
